156 related articles for article (PubMed ID: 37086333)
21. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
Baas DJH; Schilham M; Hermsen R; de Baaij JMS; Vrijhof HJEJ; Hoekstra RJ; Sedelaar JPM; Küsters-Vandevelde HVN; Gotthardt M; Wijers CHW; van Basten JP; Somford DM
Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):65-70. PubMed ID: 34471231
[TBL] [Abstract][Full Text] [Related]
22. The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer.
Meijer D; Ettema RH; van Leeuwen PJ; van der Kwast TH; van der Poel HG; Donswijk ML; Oprea-Lager DE; Bekers EM; Vis AN
BJU Int; 2023 Mar; 131(3):330-338. PubMed ID: 36069585
[TBL] [Abstract][Full Text] [Related]
23. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
24. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
25.
Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
[TBL] [Abstract][Full Text] [Related]
26. Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes.
Linxweiler J; Saar M; Al-Kailani Z; Janssen M; Ezziddin S; Stöckle M; Siemer S; Ohlmann CH
Surg Oncol; 2018 Jun; 27(2):138-145. PubMed ID: 29937163
[TBL] [Abstract][Full Text] [Related]
27.
Ferraro DA; Muehlematter UJ; Garcia Schüler HI; Rupp NJ; Huellner M; Messerli M; Rüschoff JH; Ter Voert EEGW; Hermanns T; Burger IA
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):147-159. PubMed ID: 31522272
[TBL] [Abstract][Full Text] [Related]
28. Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
Amiel T; Würnschimmel C; Heck M; Horn T; Nguyen N; Budäus L; Knipper S; Wenzel M; Rauscher I; Eiber M; Wang H; Maurer T
J Urol; 2021 Jun; 205(6):1663-1670. PubMed ID: 33535796
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study.
Gandaglia G; Mazzone E; Stabile A; Pellegrino A; Cucchiara V; Barletta F; Scuderi S; Robesti D; Leni R; Samanes Gajate AM; Picchio M; Gianolli L; Brembilla G; De Cobelli F; van Oosterom MN; van Leeuwen FWB; Montorsi F; Briganti A
Eur Urol; 2022 Oct; 82(4):411-418. PubMed ID: 35879127
[TBL] [Abstract][Full Text] [Related]
30. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol; 2020 Dec; 78(6):779-782. PubMed ID: 32624281
[TBL] [Abstract][Full Text] [Related]
31. Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer.
Barbosa ÁRG; Amaral BS; Lourenço DB; Bianco B; Gushiken FA; Apezzato M; Silva JF; Cunha MLD; Filippi RZ; Baroni RH; Lemos GC; Carneiro A
Einstein (Sao Paulo); 2022; 20():eAO6599. PubMed ID: 35584444
[TBL] [Abstract][Full Text] [Related]
32. High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation.
Rahman LA; Rutagengwa D; Lin P; Lin M; Yap J; Lai K; Mancuso P; Rathore P; Haghighi K; Gassner P; Wong LH; Lalak N
Cancer Imaging; 2019 Dec; 19(1):86. PubMed ID: 31829288
[TBL] [Abstract][Full Text] [Related]
33. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
Hermsen R; Wedick EBC; Vinken MJM; van Kalmthout LWM; Küsters-Vandevelde HVN; Wijers CHW; Somford DM; van Basten JA
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3929-3937. PubMed ID: 35543733
[TBL] [Abstract][Full Text] [Related]
34. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
Kopp D; Kopp J; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz PI; Salomon G; Wiggermann P; Hammerer P; Schiffmann J
Urol Int; 2022; 106(1):56-62. PubMed ID: 33965965
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic Accuracy of
Cantiello F; Gangemi V; Cascini GL; Calabria F; Moschini M; Ferro M; Musi G; Butticè S; Salonia A; Briganti A; Damiano R
Urology; 2017 Aug; 106():139-145. PubMed ID: 28438628
[TBL] [Abstract][Full Text] [Related]
36. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer.
Gondoputro W; Scheltema MJ; Blazevski A; Doan P; Thompson JE; Amin A; Geboers B; Agrawal S; Siriwardana A; Van Leeuwen PJ; van Oosterom MN; Van Leeuwen FWB; Emmett L; Stricker PD
J Nucl Med; 2022 Nov; 63(11):1659-1664. PubMed ID: 35241483
[TBL] [Abstract][Full Text] [Related]
37. Prospective evaluation of the performance of [
Abufaraj M; Grubmüller B; Zeitlinger M; Kramer G; Seitz C; Haitel A; Baltzer P; Hacker M; Wadsak W; Pfaff S; Wiatr T; Mitterhauser M; Shariat SF; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2169-2177. PubMed ID: 31254037
[TBL] [Abstract][Full Text] [Related]
38. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
39. Comparing the Diagnostic Performance of Multiparametric Prostate MRI Versus 68Ga-PSMA PET-CT in the Evaluation Lymph Node Involvement and Extraprostatic Extension.
Arslan A; Karaarslan E; Güner AL; Sağlıcan Y; Tuna MB; Kural AR
Acad Radiol; 2022 May; 29(5):698-704. PubMed ID: 32768351
[TBL] [Abstract][Full Text] [Related]
40. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
Budäus L; Leyh-Bannurah SR; Salomon G; Michl U; Heinzer H; Huland H; Graefen M; Steuber T; Rosenbaum C
Eur Urol; 2016 Mar; 69(3):393-6. PubMed ID: 26116958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]